ASAM 2026
When social media shapes benzo tapering: what clinicians need to know
Clinical Takeaway: Proactively ask patients about online tapering information and align evidence-based guidance (e.g., 5%–10% dose reductions every 2–4 weeks) with patient concerns to improve trust, adherence, and outcomes.
Patients increasingly rely on social media for benzodiazepine tapering advice, often encountering misinformation that can undermine safe, individualized treatment plans.
Benzodiazepine use has declined nationally, yet risks tied to long-term use—including cognitive impairment, falls, and overdose—remain substantial, especially in older adults. Combined benzodiazepine–opioid use carries up to a twofold higher mortality risk, and benzodiazepines are involved in as many as 70% of opioid overdose deaths.
Against this clinical backdrop, social media is playing a growing—and often underrecognized—role in how patients approach tapering. An analysis of 11,630 benzodiazepine-related tweets found that 73% contained information not aligned with scientific evidence, while only 6% referenced healthcare professionals. Many posts emphasized efficacy (48%) or promoted unsafe co-use with substances (23%), reflecting mixed messaging that can distort patient perceptions.
Survey data underscore the impact: in an online cohort of 1,207 respondents, 76% said their clinician never informed them that benzodiazepines were intended for short-term use or that discontinuation could be difficult. Another questionnaire found 82% of respondents were actively tapering, citing withdrawal symptoms, limited clinician support, and lack of structured resources as key barriers.
These influences may drive patients toward rigid or non-evidence-based tapering strategies (e.g., hyper-focused dose reductions or peer-shared schedules), sometimes leading to withdrawal complications or treatment disengagement.
“Online resources can be helpful for psychosocial support but may contain misinformation,” the authors noted, emphasizing the importance of clinician-guided care.
Current ASAM guidance supports individualized tapering, typically starting with 5%–10% dose reductions (not exceeding 25% every 2 weeks), with shared decision-making and flexibility central to success.
Source: Reinstatler KM & Bebo DJ. (2026, April 24). Unprescribed influence: Navigating benzodiazepine tapering in the age of social media. Presentation at the ASAM 57th Annual Conference.